Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies
Purpose: Osteopontin (OPN) is an integrin-binding protein overexpressed in various experimental models of malignancy and appears to be involved in tumorigenesis and metastasis. Although various studies have assessed OPN protein levels in several tumor types, a broad survey of OPN expression in human...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2004-01, Vol.10 (1), p.184-190 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 190 |
|---|---|
| container_issue | 1 |
| container_start_page | 184 |
| container_title | Clinical cancer research |
| container_volume | 10 |
| creator | COPPOLA, Domenico SZABO, Marianna BOULWARE, David MURACA, Patrick ALSARRAJ, Marwan CHAMBERS, Ann F YEATMAN, Timothy J |
| description | Purpose: Osteopontin (OPN) is an integrin-binding protein overexpressed in various experimental models of malignancy and appears to
be involved in tumorigenesis and metastasis. Although various studies have assessed OPN protein levels in several tumor types,
a broad survey of OPN expression in human neoplasia under the same experimental conditions has not been carried out.
Experimental Design: We used immunohistochemistry to detect OPN in a selection of 350 human tumors and 113 normal tissues, from a variety of body
sites, using stage-oriented human cancer tissue arrays. Tumors included malignancies from breast (26), ovary (22), endometrium
(14), esophagus (10), stomach (11), pancreas (16), bile duct (1), liver (9), colon (20), kidney (53), bladder (33), prostate
(28), head and neck (60), salivary glands (14), lung (17), skin (6), and brain (10).
Results: High cytoplasmic OPN staining was observed in 100% of gastric carcinomas, 85% of colorectal carcinomas, 82% of transitional
cell carcinomas of the renal pelvis, 81% of pancreatic carcinomas, 72% of renal cell carcinomas, 71% of lung and endometrial
carcinomas, 70% of esophageal carcinomas, 58% of squamous cell carcinomas of the head and neck, and 59% of ovarian carcinomas.
Although OPN expression was identified in a good number of bladder, prostate, and brain tumors, the majority of 6 skin cancers,
11 of 14 salivary gland cancers, 2 thyroid carcinomas, and 23 of 26 breast cancers revealed low OPN positivity or were negative.
When considering all sites, OPN expression significantly correlated with tumor stage (Spearman’s correlation coefficient,
P = 0.0002). OPN score and stage were also significantly correlated for specific cancer sites including bladder ( P = 0.01), colon ( P = 0.004), kidney ( P = 0.0001), larynx ( P = 0.035), mouth ( P = 0.046), and salivary gland ( P = 0.011).
Conclusions: This study reports the broad distribution of OPN in human tumors from different body sites, suggesting involvement of this
protein in tumor formation. The strong correlation between pathological stage and OPN across multiple tumor types suggests
a role for OPN in tumor progression. |
| doi_str_mv | 10.1158/1078-0432.CCR-1405-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80110068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80110068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-7764fb1e06b48da07e1e0b1ca03842cd22af5173346a6c5be424dc9bdc9bc6783</originalsourceid><addsrcrecordid>eNpFkU1P3DAQhi3Uiq_2HyDkS-EUasdf4YgiWiohgVraHq2JM9k1ysaL7VXLv6-zuxUHa-bwvKOZx4SccXbFuWo-c2aaiklRX7Xt94pLpqr6gBxzpUwlaq3elf4_ckROUnpmjEvO5CE54tIIKXVzTEIbYsQRsg8TDQN9SBnDOkzZT_Qxhoyl3v5dR0xpJmDq6SPkZRjDwjsY6Y8MC6TgYkiJAv3te6S_IHrMr_O4p80qRHrnU94mMH0g7wcYE37c11Py88vtU3tX3T98_dbe3FdOGpMrY7QcOo5Md7LpgRksfccdMNHI2vV1DYPiRgipQTvVoaxl7667-TltGnFKLnZz1zG8bDBlu_LJ4TjChGGTbMM4Z0zPoNyB2xMiDnYd_Qriq-XMzqLtbNHOFm0RbWfRti6x8_38TbfC_i20N1uAT3sAUhE1RJicT2-cKhtroQp3ueOWfrH84yNaV0gsn5IQoltu17C8keIfO1WVkA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80110068</pqid></control><display><type>article</type><title>Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>COPPOLA, Domenico ; SZABO, Marianna ; BOULWARE, David ; MURACA, Patrick ; ALSARRAJ, Marwan ; CHAMBERS, Ann F ; YEATMAN, Timothy J</creator><creatorcontrib>COPPOLA, Domenico ; SZABO, Marianna ; BOULWARE, David ; MURACA, Patrick ; ALSARRAJ, Marwan ; CHAMBERS, Ann F ; YEATMAN, Timothy J</creatorcontrib><description>Purpose: Osteopontin (OPN) is an integrin-binding protein overexpressed in various experimental models of malignancy and appears to
be involved in tumorigenesis and metastasis. Although various studies have assessed OPN protein levels in several tumor types,
a broad survey of OPN expression in human neoplasia under the same experimental conditions has not been carried out.
Experimental Design: We used immunohistochemistry to detect OPN in a selection of 350 human tumors and 113 normal tissues, from a variety of body
sites, using stage-oriented human cancer tissue arrays. Tumors included malignancies from breast (26), ovary (22), endometrium
(14), esophagus (10), stomach (11), pancreas (16), bile duct (1), liver (9), colon (20), kidney (53), bladder (33), prostate
(28), head and neck (60), salivary glands (14), lung (17), skin (6), and brain (10).
Results: High cytoplasmic OPN staining was observed in 100% of gastric carcinomas, 85% of colorectal carcinomas, 82% of transitional
cell carcinomas of the renal pelvis, 81% of pancreatic carcinomas, 72% of renal cell carcinomas, 71% of lung and endometrial
carcinomas, 70% of esophageal carcinomas, 58% of squamous cell carcinomas of the head and neck, and 59% of ovarian carcinomas.
Although OPN expression was identified in a good number of bladder, prostate, and brain tumors, the majority of 6 skin cancers,
11 of 14 salivary gland cancers, 2 thyroid carcinomas, and 23 of 26 breast cancers revealed low OPN positivity or were negative.
When considering all sites, OPN expression significantly correlated with tumor stage (Spearman’s correlation coefficient,
P = 0.0002). OPN score and stage were also significantly correlated for specific cancer sites including bladder ( P = 0.01), colon ( P = 0.004), kidney ( P = 0.0001), larynx ( P = 0.035), mouth ( P = 0.046), and salivary gland ( P = 0.011).
Conclusions: This study reports the broad distribution of OPN in human tumors from different body sites, suggesting involvement of this
protein in tumor formation. The strong correlation between pathological stage and OPN across multiple tumor types suggests
a role for OPN in tumor progression.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-1405-2</identifier><identifier>PMID: 14734468</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Aged ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Case-Control Studies ; Disease Progression ; Female ; Humans ; Immunoenzyme Techniques ; Male ; Medical sciences ; Neoplasms - metabolism ; Neoplasms - pathology ; Osteopontin ; Pharmacology. Drug treatments ; Phosphoproteins - metabolism ; Sialoglycoproteins - metabolism ; Tumors</subject><ispartof>Clinical cancer research, 2004-01, Vol.10 (1), p.184-190</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-7764fb1e06b48da07e1e0b1ca03842cd22af5173346a6c5be424dc9bdc9bc6783</citedby><cites>FETCH-LOGICAL-c477t-7764fb1e06b48da07e1e0b1ca03842cd22af5173346a6c5be424dc9bdc9bc6783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15424635$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14734468$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>COPPOLA, Domenico</creatorcontrib><creatorcontrib>SZABO, Marianna</creatorcontrib><creatorcontrib>BOULWARE, David</creatorcontrib><creatorcontrib>MURACA, Patrick</creatorcontrib><creatorcontrib>ALSARRAJ, Marwan</creatorcontrib><creatorcontrib>CHAMBERS, Ann F</creatorcontrib><creatorcontrib>YEATMAN, Timothy J</creatorcontrib><title>Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: Osteopontin (OPN) is an integrin-binding protein overexpressed in various experimental models of malignancy and appears to
be involved in tumorigenesis and metastasis. Although various studies have assessed OPN protein levels in several tumor types,
a broad survey of OPN expression in human neoplasia under the same experimental conditions has not been carried out.
Experimental Design: We used immunohistochemistry to detect OPN in a selection of 350 human tumors and 113 normal tissues, from a variety of body
sites, using stage-oriented human cancer tissue arrays. Tumors included malignancies from breast (26), ovary (22), endometrium
(14), esophagus (10), stomach (11), pancreas (16), bile duct (1), liver (9), colon (20), kidney (53), bladder (33), prostate
(28), head and neck (60), salivary glands (14), lung (17), skin (6), and brain (10).
Results: High cytoplasmic OPN staining was observed in 100% of gastric carcinomas, 85% of colorectal carcinomas, 82% of transitional
cell carcinomas of the renal pelvis, 81% of pancreatic carcinomas, 72% of renal cell carcinomas, 71% of lung and endometrial
carcinomas, 70% of esophageal carcinomas, 58% of squamous cell carcinomas of the head and neck, and 59% of ovarian carcinomas.
Although OPN expression was identified in a good number of bladder, prostate, and brain tumors, the majority of 6 skin cancers,
11 of 14 salivary gland cancers, 2 thyroid carcinomas, and 23 of 26 breast cancers revealed low OPN positivity or were negative.
When considering all sites, OPN expression significantly correlated with tumor stage (Spearman’s correlation coefficient,
P = 0.0002). OPN score and stage were also significantly correlated for specific cancer sites including bladder ( P = 0.01), colon ( P = 0.004), kidney ( P = 0.0001), larynx ( P = 0.035), mouth ( P = 0.046), and salivary gland ( P = 0.011).
Conclusions: This study reports the broad distribution of OPN in human tumors from different body sites, suggesting involvement of this
protein in tumor formation. The strong correlation between pathological stage and OPN across multiple tumor types suggests
a role for OPN in tumor progression.</description><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Case-Control Studies</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - pathology</subject><subject>Osteopontin</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphoproteins - metabolism</subject><subject>Sialoglycoproteins - metabolism</subject><subject>Tumors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1P3DAQhi3Uiq_2HyDkS-EUasdf4YgiWiohgVraHq2JM9k1ysaL7VXLv6-zuxUHa-bwvKOZx4SccXbFuWo-c2aaiklRX7Xt94pLpqr6gBxzpUwlaq3elf4_ckROUnpmjEvO5CE54tIIKXVzTEIbYsQRsg8TDQN9SBnDOkzZT_Qxhoyl3v5dR0xpJmDq6SPkZRjDwjsY6Y8MC6TgYkiJAv3te6S_IHrMr_O4p80qRHrnU94mMH0g7wcYE37c11Py88vtU3tX3T98_dbe3FdOGpMrY7QcOo5Md7LpgRksfccdMNHI2vV1DYPiRgipQTvVoaxl7667-TltGnFKLnZz1zG8bDBlu_LJ4TjChGGTbMM4Z0zPoNyB2xMiDnYd_Qriq-XMzqLtbNHOFm0RbWfRti6x8_38TbfC_i20N1uAT3sAUhE1RJicT2-cKhtroQp3ueOWfrH84yNaV0gsn5IQoltu17C8keIfO1WVkA</recordid><startdate>20040101</startdate><enddate>20040101</enddate><creator>COPPOLA, Domenico</creator><creator>SZABO, Marianna</creator><creator>BOULWARE, David</creator><creator>MURACA, Patrick</creator><creator>ALSARRAJ, Marwan</creator><creator>CHAMBERS, Ann F</creator><creator>YEATMAN, Timothy J</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040101</creationdate><title>Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies</title><author>COPPOLA, Domenico ; SZABO, Marianna ; BOULWARE, David ; MURACA, Patrick ; ALSARRAJ, Marwan ; CHAMBERS, Ann F ; YEATMAN, Timothy J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-7764fb1e06b48da07e1e0b1ca03842cd22af5173346a6c5be424dc9bdc9bc6783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Case-Control Studies</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - pathology</topic><topic>Osteopontin</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphoproteins - metabolism</topic><topic>Sialoglycoproteins - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>COPPOLA, Domenico</creatorcontrib><creatorcontrib>SZABO, Marianna</creatorcontrib><creatorcontrib>BOULWARE, David</creatorcontrib><creatorcontrib>MURACA, Patrick</creatorcontrib><creatorcontrib>ALSARRAJ, Marwan</creatorcontrib><creatorcontrib>CHAMBERS, Ann F</creatorcontrib><creatorcontrib>YEATMAN, Timothy J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>COPPOLA, Domenico</au><au>SZABO, Marianna</au><au>BOULWARE, David</au><au>MURACA, Patrick</au><au>ALSARRAJ, Marwan</au><au>CHAMBERS, Ann F</au><au>YEATMAN, Timothy J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2004-01-01</date><risdate>2004</risdate><volume>10</volume><issue>1</issue><spage>184</spage><epage>190</epage><pages>184-190</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: Osteopontin (OPN) is an integrin-binding protein overexpressed in various experimental models of malignancy and appears to
be involved in tumorigenesis and metastasis. Although various studies have assessed OPN protein levels in several tumor types,
a broad survey of OPN expression in human neoplasia under the same experimental conditions has not been carried out.
Experimental Design: We used immunohistochemistry to detect OPN in a selection of 350 human tumors and 113 normal tissues, from a variety of body
sites, using stage-oriented human cancer tissue arrays. Tumors included malignancies from breast (26), ovary (22), endometrium
(14), esophagus (10), stomach (11), pancreas (16), bile duct (1), liver (9), colon (20), kidney (53), bladder (33), prostate
(28), head and neck (60), salivary glands (14), lung (17), skin (6), and brain (10).
Results: High cytoplasmic OPN staining was observed in 100% of gastric carcinomas, 85% of colorectal carcinomas, 82% of transitional
cell carcinomas of the renal pelvis, 81% of pancreatic carcinomas, 72% of renal cell carcinomas, 71% of lung and endometrial
carcinomas, 70% of esophageal carcinomas, 58% of squamous cell carcinomas of the head and neck, and 59% of ovarian carcinomas.
Although OPN expression was identified in a good number of bladder, prostate, and brain tumors, the majority of 6 skin cancers,
11 of 14 salivary gland cancers, 2 thyroid carcinomas, and 23 of 26 breast cancers revealed low OPN positivity or were negative.
When considering all sites, OPN expression significantly correlated with tumor stage (Spearman’s correlation coefficient,
P = 0.0002). OPN score and stage were also significantly correlated for specific cancer sites including bladder ( P = 0.01), colon ( P = 0.004), kidney ( P = 0.0001), larynx ( P = 0.035), mouth ( P = 0.046), and salivary gland ( P = 0.011).
Conclusions: This study reports the broad distribution of OPN in human tumors from different body sites, suggesting involvement of this
protein in tumor formation. The strong correlation between pathological stage and OPN across multiple tumor types suggests
a role for OPN in tumor progression.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>14734468</pmid><doi>10.1158/1078-0432.CCR-1405-2</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2004-01, Vol.10 (1), p.184-190 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80110068 |
| source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Aged Antineoplastic agents Biological and medical sciences Biomarkers, Tumor - metabolism Case-Control Studies Disease Progression Female Humans Immunoenzyme Techniques Male Medical sciences Neoplasms - metabolism Neoplasms - pathology Osteopontin Pharmacology. Drug treatments Phosphoproteins - metabolism Sialoglycoproteins - metabolism Tumors |
| title | Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A23%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20of%20Osteopontin%20Protein%20Expression%20and%20Pathological%20Stage%20across%20a%20Wide%20Variety%20of%20Tumor%20Histologies&rft.jtitle=Clinical%20cancer%20research&rft.au=COPPOLA,%20Domenico&rft.date=2004-01-01&rft.volume=10&rft.issue=1&rft.spage=184&rft.epage=190&rft.pages=184-190&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-1405-2&rft_dat=%3Cproquest_cross%3E80110068%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80110068&rft_id=info:pmid/14734468&rfr_iscdi=true |